Astra taps new North American CFO; FDA reviews drug's eyelash boost;

> AstraZeneca appointed Graham Baker as its new vice president and CFO of North American operations. Report

> FDA staffers said a glaucoma drug from Allergan appears to make eyelashes longer and fuller, and an advisory committee will assess the safety of that new use at a meeting today. Report

> Pfizer's attempts to settle Nigerian litigation and claims over its 1996 Trovan trial there have been complicated by a fictitious list of victims, newspapers report. Report

> GlaxoSmithKline announced a $250,000 donation to The Carter Center to help Ethiopia launch a program to eliminate lymphatic filariasis. Release

> GSK also announced it would cut the price of its human papillomavirus vaccine Cervarix in South Africa to about $43 per dose from about $67. Report

> Auxilium Pharmaceuticals and CPEX Pharmaceuticals sued Upsher-Smith Laboratories for infringement of CPEX's patent on Testim testosterone gel. Release

> Perrigo settled a patent-infringement lawsuit with Schering-Plough, which will allow Perrigo to launch a generic version of allergy drug Clarinex on July 1, 2012. Release

> FDA staffers said a glaucoma drug from Allergan appears to make eyelashes longer and fuller, and an advisory committee will assess the safety of that new use at a meeting today. Report

> A high dose of the chemo drug daunorubicin, sold under the brand name Cerubidine by Bedford Laboratories, prolonged survival for patients with previously untreated acute myeloid leukemia, preliminary study results show. Report

> Combining a calcium-channel blocker and an ACE inhibitor worked better at preventing heart problems in patients high blood pressure than did a diuretic combined with an ACE inhibitor, a large clinical trial suggests. Report

And Finally... The old adage about the world smiling with you is right, researchers say: Happiness is contagious. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.